Form 4 for VIR Vir Biotechnology, Inc.
Accepted 2026-02-24 00:00:00 ET · period of report 2026-02-22 · accession 0001628280-26-011330 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-24 | 2026-02-22 | VIR | O'Byrne Jason | EVP, CFO | A - Grant | $0.00 | +55.0K | 166.3K | +49% | $0 |
| D | 2026-02-24 | 2026-02-23 | VIR | O'Byrne Jason | EVP, CFO | S - Sale | $7.45 | -2,089 | 164.2K | -1% | -$15.6K |
| D | 2026-02-24 | 2026-02-22 | VIR | O'Byrne Jason | EVP, CFO | A - Grant | $0.00 | +110.0K | 110.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-22 | A | A | 55,000 | $0.00 | 166,338 | D | — | — | (F2) Includes 637 shares of common stock acquired by the Reporting Person on November 28, 2025, pursuant to an employee stock purchase program. |
| 2 | Common | Common Stock | 2026-02-23 | S | D | 2,089 | $7.45 | 164,249 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-02-22 | A | A | 110,000 | $0.00 | 110,000 | D | $7.56 · — to 2036-02-21 | 110,000 Common Stock | (F4) 25% of the shares subject to the stock option will vest and become exercisable on February 22, 2027, and the remaining shares will vest in 36 equal monthly installments thereafter. |